Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Other EventsItem 8.01 Other Events.
On April 18, 2018, Spotlight Innovation Inc. issued a Press Release stating that its subsidiary Celtic Biotech Iowa announces results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer. A copy of this Press Release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit to Item 8.01 hereof:
|
Exhibit 99.1 |
Press Release dated April 18, 2018. |
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SPOTLIGHT INNOVATION INC. |
||
|
Dated: August 18, 2018 |
By: |
/s/ John William Pim |
|
John William Pim |
||
|
Chief Financial Officer |
||
EXHIBIT INDEX
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit Spotlight Innovation Inc. ExhibitEX-99.1 2 stlt_ex991.htm PRESS RELEASE stlt_ex991.htmEXHIBIT 99.1 Spotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer URBANDALE,…To view the full exhibit click here
About Spotlight Innovation Inc. (OTCMKTS:STLT)
Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.
